Although 300 million people suffer from asthma globally, with 250,000 estimated deaths, for many living in low- and middle-income countries, access to quality-assured, affordable asthma-essential medicines still remains a distant dream according to a study published in the journal PharmacoEcoomics.
The study, conducted by Zaheer Babar from the School of …